

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

VL51

RRID:CVCL_3169

Type: Cell Line

Proper Citation

JCRB Cat# NIHS0247, RRID:CVCL_3169

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3169

Proper Citation: JCRB Cat# NIHS0247, RRID:CVCL_3169

Description: Cell line VL51 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Splenic marginal zone lymphoma

Defining Citation: [PMID:8551798](#), [PMID:20215515](#), [PMID:27397505](#), [PMID:29892436](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: VL51

Synonyms: SLVL, VL-51

Cross References: CLO:CLO_0050869, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472064, cancercellines:CVCL_3169, Cell_Model_Passport:SIDM00374, Cosmic-CLP:1331032, DepMap:ACH-002062, EGA:EGAS00001000978, FANTOM5_SSTAR:10424-106D1, GDSC:1331032, GEO:GSM827255, GEO:GSM866167, GEO:GSM1035345, GEO:GSM1035346, GEO:GSM1670458, JCRB:JCRB0159, JCRB:NIHS0247, LINCS_LDP:LCL-1952, PharmacDB:SLVL_1427_2019, PRIDE:PXD030304, Progenetix:CVCL_3169, RCB:RCB1702, Wikidata:Q54993196

ID: CVCL_3169

Vendor: JCRB

Catalog Number: NIHS0247

Record Creation Time: 20220427T221709+0000

Record Last Update: 20260905T182723+0000

Ratings and Alerts

No rating or validation information has been found for VL51.

Warning: Discontinued: JCRB; NIHS0247

Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.